RPTOR and renal carcinoma: Our identification of RAPTOR up-regulation as a novel mediator of resistance to mTOR kinase inhibition in renal cancer suggests that RAPTOR expression should be included in the pharmacodynamic evaluation of mTOR kinase inhibitor trials.